Emergence Agitation of Sevoflurane in Pediatric (NCT06830564) | Clinical Trial Compass
CompletedPhase 2/3
Emergence Agitation of Sevoflurane in Pediatric
Egypt126 participantsStarted 2024-05-01
Plain-language summary
Low dose nalbuphine versus dexmedetomidine on prevention of emergence agitation in children
Who can participate
Age range4 Years – 10 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age 4 - 10 years.
* Sex: male and female
* Patients with ASA classification I and II
Exclusion Criteria:
* Refusal of the caregiver to give written informed consent.
* History of allergy to the medications used in the study.
* psychiatric disorder.
* ASA classification III - IV.
* Fever, cough, asthma or upper respiratory tract infection.
* surgery more than 2 hours
* Hearing defect that limits communication.
* Neurological disorder .
* History of malignant hyperthermia.
* surgeries more than 2 hours.
What they're measuring
1
incidence of emergence agitation after sevoflurane anaesthesia